MPX International Corporation announced that its wholly-owned subsidiary, Canveda Inc., a licence holder under the Cannabis Act (Canada), has entered into a production and distribution agreement with Panaxia Pharmaceutical Industries Israel Ltd. for the packaging and distribution of cannabis which will be marketed and sold in Israel under Canveda's medical brand "Salus BioPharma". A first shipment of 100 kg of high-quality cannabis flower will be shipped from Canada to Israel as soon as an export permit from Health Canada is acquired. All the required import permits from Israel have been issued. Panaxia uses high-quality cannabis flower to manufacture and distribute a variety of standardized, pharma-grade, smokeless, measured dosage cannabinoid-based products including sublingual tablets, slow release tablets, pastilles, rectal suppositories, vaginal suppositories, skincare ointments, topical patches and oral spray inhalers. The Salus BioPharma products will be sold to patients with a variety of conditions such as PTSD, chronic pain, cancer, epilepsy, Parkinson's, Alzheimer's, anorexia and HIV/AIDS.